Imipenem
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Imipenem
Imipenem is a approved stage product being developed by Merck for Sepsis. The current trial status is unknown. This product is registered under clinical trial identifier NCT02616354. Target conditions include Sepsis.
What happened to similar drugs?
8 of 18 similar drugs in Sepsis were approved
Approved (8) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02616354 | Approved | UNKNOWN |
Competing Products
20 competing products in Sepsis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alkaline Phosphatase + Placebo | AM-Pharma | Phase 2 | 25 |
| Drotrecogin alfa (activated) | Eli Lilly | Phase 2 | 35 |
| Meropenem | Pfizer | Approved | 43 |
| Cefiderocol | Shionogi | Phase 1 | 29 |
| eritoran tetrasodium + Placebo | Eisai | Phase 3 | 40 |
| E5564 | Eisai | Phase 2 | 35 |
| Drotrecogin Alfa (Activated) + placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin Alfa (activated) | Eli Lilly | Approved | 43 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 40 |
| sPLA2 Inhibitor | Eli Lilly | Phase 1/2 | 32 |
| Drotrecogin alfa (activated) | Eli Lilly | Approved | 43 |
| Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin | Eli Lilly | Approved | 43 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 43 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 43 |
| AZD9773 (CytoFab) | AstraZeneca | Phase 2 | 35 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD4144 + Placebo | AstraZeneca | Phase 2 | 42 |